Key facts
- This page summarizes Eric Devroe's Form 4 filing for Acrivon Therapeutics, Inc. (ACRV).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 Jun 2023, 16:15.
Eric Devroe - 05 Jun 2023 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- ACRV
- Reported as of
- 05 Jun 2023
- Net transaction value
- +$9,594
- SEC form
- 4
- Accepted by SEC
- 06 Jun 2023, 16:15:49 UTC
- Prior SEC filing
- 16 Nov 2022
- Next SEC filing
- 16 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Devroe filed Form 4 for Acrivon Therapeutics, Inc. (ACRV) on 06 Jun 2023.
Change
- Previous filing in this sequence was filed on 16 Nov 2022.
- Current net transaction value: +$9,594.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACRV
transaction
Common Stock
Options Exercise
- Transaction value
- $9,594
- Shares
- +9,225
- Change %
- +17%
- Price
- $1.04*
- Shares after
- 62,883
- Date
- 05 Jun 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACRV
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -9,225
- Change %
- -8.7%
- Price
- $0.000000
- Shares after
- 96,615
- Date
- 05 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,225
- Exercise price
- $1.04
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Twenty-five percent (25%) of the shares subject to the option vested on October 5, 2021, and the remaining shares subject to the option vested or shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
SEC remarks
Exhibit List - Exhibit 24 - Power of Attorney